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A B S T R A C T
Background
Uncomplicated urinary tract infection (UTI) is the most common bacterial infection in women, characterised by dysuria and urinary
frequency. Urinary alkalisers are widely used in some countries for the symptomatic treatment of uncomplicated UTI, and they are
recommended in some national formularies. However, there is a lack of empirical evidence to support their use for UTI and some
healthcare guidelines advise against their use.
Objectives
We aimed to look at the benefits and harms of the use of urinary alkalisers for the treatment of uncomplicated UTIs in adult women.
Search methods
We searched the Cochrane Kidney and Transplant Specialised Register to 19 January 2016 through contact with the Trials Search Co-
ordinator using search terms relevant to this review.
Selection criteria
All randomised controlled trials (RCTs) and quasi-RCTs on the use of (any) urinary alkalisers (either exclusively or non-exclusively)
for the symptomatic treatment of uncomplicated UTI amongst women aged 16 and over, were included. Studies were eligible if they
included patients whose diagnosis of UTI was decided by symptoms alone, or positive urine dipstick test or urine culture; and patients
with recurrent UTI, provided patients had no symptoms of UTI in the two weeks prior to the onset of symptoms that lead them to
seek medical advice. Studies were ineligible if they studied patients with complicated UTIs; immune-compromising conditions; acute
pyelonephritis; or chronic conditions such as interstitial cystitis.
Data collection and analysis
Three authors independently assessed and screened papers, and this was repeated by two separate authors (independently). An additional
investigator acted as arbitrator, where necessary. There were no papers which fulfilled the inclusion criteria for this review, and therefore
no data extraction was performed.
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Main results
Our search identified 172 potential studies for inclusion. However, following assessment none fulfilled the inclusion criteria for this
review.
Authors’ conclusions
Until relevant evidence is generated from randomised trials, the safety and efficacy of urinary alkalisers for the symptomatic treatment
of uncomplicated UTI remains unknown.
P L A I N L A N G U A G E S U M M A R Y
Urinary alkalisation for uncomplicated urinary tract infections
Urinary tract infection (UTI) is themost common form of bacterial infection among women and can cause pain and frequent urination.
Urinary alkalisers are medications that reduce the acidity of urine; these are commonly purchased over the counter, or prescribed by
doctors to treat the symptoms of UTI.
We aimed to investigate the benefits and harms of urinary alkalisers for the treatment of UTI. We searched the literature to 19 January
2016 but found no randomised controlled trials (RCTs) undertaken to investigate these agents that met our study inclusion criteria.
We were unable to judge the benefits or harms of the use urinary alkalisers in the context of UTI.
It is important that further research in the form of RCTs be carried out to determine the benefits or harms of urinary alkalisers.
B A C K G R O U N D
Description of the condition
Urinary tract infections (UTIs) are the most common bacterial
infections in women, most of which are uncomplicated (Foxman
2003). UTIs are considered uncomplicated in the absence of uri-
nary tract abnormalities, obstruction or resistant pathogens, preg-
nancy, immunocompromised state, or involvement of the upper
renal tract. The term ’uncomplicated’ generally does not apply to
UTIs in men.
Standard conventional management of suspected UTI is to treat
empirically with antibiotics, although studies have challenged this
approach (Bleidorn 2010; Richards 2005). UTI can then be con-
firmed with urine microscopy and culture, from a urine sample
taken prior to the commencement of antibiotics. Whatever the
role of antibiotics, women often seek relief from the symptoms of
UTI until either the infection is cleared with antibiotics or resolves
spontaneously. Uncomplicated UTIs often remit spontaneously
without antibiotics: a recent pilot RCT found that symptomatic
treatment of uncomplicated UTI with nonsteroidal anti-inflam-
matory drugs (NSAIDs) was non-inferior to antimicrobial therapy
with ciprofloxacin (Bleidorn 2010). Nonetheless, an earlier study
also found that women with symptoms of UTI who are culture-
negative respond to antibiotics (Richards 2005).
Description of the intervention
Several clinical guidelines for UTI treatment advise first-line use of
antibiotics (ACOG2008; Grabe 2010; IDSA/ESMI 2011). How-
ever, until infection has cleared (due to either antimicrobial ther-
apy or spontaneous remission), symptoms may be troublesome.
The use of urinary alkalisers for the symptomatic treatment of
uncomplicated UTI is very common in some countries. For ex-
ample, more than one million units of urinary alkalisers are sold
in Australia annually; many of these are used specifically for UTIs
and acute culture-negative cystitis. Use of urinary alkalisers for the
symptomatic treatment of UTI and cystitis appear in MIMS Aus-
tralia and other national formularies (eMC 2016; MIMS 2016).
Use is also widely promoted by primary healthcare practitioners
(Murtagh 2015; Phelps 2011). Literature supporting benefits from
use of these agents is sparse; some guidelines specifically state that
they are not recommended (NICE 2009). The most commonly
available urinary alkalisers are potassium citrate, sodium citrate,
and sodium bicarbonate.
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How the intervention might work
Urinary alkalisers primarily work to raise urine pH, which in the-
ory, aids in the symptomatic relief of dysuria. Dysuria and urinary
frequency are the most common and bothersome symptoms of
UTI and acute culture-negative cystitis (Munday 1990; Spooner
1984).
Urinary pathogens, such as Proteus mirabilis can also increase uri-
nary pH and are associated with symptoms of dysuria and urinary
frequency (Franz 1999); however, it has been suggested elsewhere
that there is no correlation between the urine pH and the sensation
of dysuria (Brumfitt 1990).
Why it is important to do this review
Uncomplicated UTI is very common, and imposes significant fi-
nancial burden. In the USA, UTI is responsible for over sevenmil-
lion physician visits annually, and account for the use of approx-
imately 15% of all community-prescribed antibiotics. The total
annual estimated cost of antibiotics for UTI in the USA exceeds
one billion dollars (Foxman 2002; Mazzulli 2002). The advent of
increasing numbers of drug resistant organisms means that avoid-
ance of unnecessary antibiotics is important.
Urinary alkalisers are widely used in certain parts of the world,
particularly Australia, for symptomatic relief of UTI and acute
culture-negative cystitis. There is however a paucity of good ev-
idence to support their use. There is also conflicting evidence
surrounding urinary alkalisation for antimicrobial eradication in
UTI. Some studies show benefit of concomitant urinary alkalisers
and antibiotic use, with reduced antibiotic minimum inhibitory
concentration when urine is at alkaline pH. Other studies show
that urine pH within the acidic range is favourable, as it can have
a bactericidal effect (Burian 2012; Carlsson 2003; Zhanel 1991).
Although we aimed to focus on symptom relief in UTI, antimi-
crobial eradication may also be important, as prolonged positive
urine culture may lead to a prolongation of symptoms.
O B J E C T I V E S
We aimed to look at the benefits and harms of the use of uri-
nary alkalisers for the treatment of uncomplicated UTIs in adult
women.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All RCTs and quasi-RCTs (RCTs in which allocation to treatment
was obtained by alternation, use of alternate medical records, date
of birth or other predictable methods) looking at the use of urinary
alkalisers (of any type) for the symptomatic relief of UTI were
eligible for inclusion.
Types of participants
Inclusion criteria
We included women aged 16 years or over with symptoms of un-
complicated UTI or cystitis; including urinary frequency, urgency
and dysuria. Participants were to be included regardless of whether
diagnoses were made based on positive urine dipstick test results,
positive urine culture, or symptoms alone. Women with recurrent
UTI were to be included if they had no symptoms of UTI in the
two weeks prior to the onset of the symptoms that lead to their
presentation to the general practitioner/health clinic.
Exclusion criteria
• Complicated UTIs, such as those requiring hospital
admission, infections associated with fevers or rigours, those
involving multidrug resistant pathogens, Neisseria gonorrhoeae
and Chlamydia trachomatis urethritis, urinary tract abnormalities,
urinary tract calculi or urinary tract obstruction
• Immunocompromising conditions
• Acute pyelonephritis
• UTI symptoms in the two weeks prior to the onset of
symptoms that lead to presentation
• Chronic conditions such as interstitial cystitis, painful
bladder syndrome, chronic pelvic pain syndrome.
Types of interventions
Any urinary alkalisers used exclusively or non-exclusively for the
treatment of symptoms of UTI were included. We aimed to com-
pare:
• Urinary alkalisers versus placebo/no treatment
• Urinary alkalisers versus antibiotics
• Urinary alkalisers + antibiotics versus antibiotics alone
• Urinary alkalisers versus NSAIDs.
Types of outcome measures
Primary outcomes
• Early and late symptoms (at days 1 to 4 and days 5 to 10):
dysuria, urinary frequency, and abdominal pain
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• Any adverse events: worsening of UTI, progression to
complicated UTI, need for hospitalisation or intravenous
antibiotics.
Secondary outcomes
• Duration of symptoms
• Severity of symptoms (negligible, mild, moderate, severe) as
measured on days 1 to 4 and days 5 to 10
• Number of return visits to the GP
• Days absent from work
• Bacterial eradication.
Search methods for identification of studies
Electronic searches
We searched Cochrane Kidney and Transplant’s Specialised Reg-
ister to 19 January 2016 through contact with the Trials Search
Co-ordinator using search terms relevant to this review. The Spe-
cialised Register contains studies identified from the following
sources.
1. Quarterly searches of the Cochrane Central Register of
Controlled Trials CENTRAL
2. Weekly searches of MEDLINE OVID SP
3. Handsearching of kidney-related journals and the
proceedings of major kidney conferences
4. Searching of the current year of EMBASE OVID SP
5. Weekly current awareness alerts for selected kidney journals
6. Searches of the International Clinical Trials Register
(ICTRP) Search Portal and ClinicalTrials.gov.
Studies contained in the SpecialisedRegister are identified through
search strategies for CENTRAL,MEDLINE, andEMBASE based
on the scope of Cochrane Kidney and Transplant. Details of
these strategies as well as a list of handsearched journals, confer-
ence proceedings and current awareness alerts are available in the
Specialised Register section of information about the Cochrane
Kidney and Transplant.
Searching other resources
1. Reference lists of clinical practice guidelines, review articles
and relevant studies.
2. Letters seeking information about unpublished or
incomplete studies to investigators known to be involved in
previous studies.
Data collection and analysis
Selection of studies
The search strategy described was used to obtain titles and ab-
stracts of studies which were relevant to the review. Titles and
abstracts were screened independently by three authors, who dis-
carded studies that were not applicable based on title and abstract
alone. Where relevance to the review was unclear based on the
title and abstract, these studies were retained, and the full papers
obtained. In the case where the full paper was not published in
English, the paper was translated to English. Four authors inde-
pendently assessed the full manuscripts of the retained papers to
determine whether the inclusion criteria were satisfied, and papers
were included or excluded based on this assessment. Where con-
sensus was not reached, an additional investigator acted as arbiter.
The screening process was repeated by two separate investigators
independently, and the same outcome was reached.
Data extraction and management
Data extraction was to be carried out independently by two au-
thors using standard data extraction forms. Studies reported in
non-English language journals were to be translated before assess-
ment. Where more than one publication of one study existed, re-
ports were to be grouped together and the publication with the
most complete data was to be used in the analyses. Where relevant
outcomes were only published in earlier versions these data were
to be used. Any discrepancies between published versions were to
be highlighted.
Assessment of risk of bias in included studies
We planned to assess risk of bias using the Cochrane risk of bias
assessment tool (Higgins 2011) (Appendix 2).
• Was there adequate sequence generation (selection bias)?
• Was allocation adequately concealed (selection bias)?
• Was knowledge of the allocated interventions adequately
prevented during the study?
◦ Participants and personnel (performance bias)
◦ Outcome assessors (detection bias)
• Were incomplete outcome data adequately addressed
(attrition bias)?
• Are reports of the study free of suggestion of selective
outcome reporting (reporting bias)?
• Was the study apparently free of other problems that could
put it at a risk of bias?
Measures of treatment effect
For dichotomous outcomes such as resolution of symptoms by day
three and day seven (dysuria, urinary frequency, abdominal pain)
and progression to complicated UTI, we planned to express results
as risk ratio (RR) with 95% confidence intervals (CI). Where
continuous scales of measurement were used to assess the effects
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of treatment, such as duration of symptoms, severity of symptoms
(negligible, mild, moderate, severe; 0 to 3), the mean difference
(MD) was to be used, or the standardised mean difference (SMD)
if different scales had been used.
Unit of analysis issues
In relation to cluster-RCTs, only studies where analyses were made
at the same level as allocation (and using summary measurements
for each cluster) were to be included. Cluster-RCTs could have
been included if statistical methods were employed to deal with
analysis at the individual level, which could account for data clus-
tering, and that statistical methods were clearly outlined in the
methods, and were sound.
Data from cross-over RCTs could also be assessed, but only the
first randomisation period was included. Complete cross-over data
were inappropriate for the intervention under review.
Urinary alkalisers could be investigated alone or in combination
with another agent(s) where the only difference between groups
was addition of a urinary alkaliser. Where possible we aimed to
combine groups with the same intervention and create a single
pair-wise comparison.
Dealing with missing data
Any further information required from original authors was to be
requested by written correspondence (e.g. emailing or writing to
corresponding author) and any relevant information obtained in
this manner was to be included in the review. Evaluation of impor-
tant numerical data such as screened, randomised patients as well
as intention-to-treat, as-treated and per-protocol population was
to be carefully performed. Attrition rates, for example drop-outs,
losses to follow-up and withdrawals were to be investigated. Issues
of missing data and imputation methods (e.g. last-observation-
carried-forward) were to be critically appraised (Higgins 2011).
Assessment of heterogeneity
We planned to analyse heterogeneity using a Chi² test on N-1
degrees of freedom, with an alpha of 0.05 used for statistical sig-
nificance, and the I² statistic (Higgins 2003).
Assessment of reporting biases
Funnel plots were to be used to assess for the potential existence
of small study bias (Higgins 2011). Because no studies met our
inclusion criteria, this could not be performed.
Data synthesis
Data were to be pooled using the random-effects model but the
fixed-effect model was also to be used to ensure robustness of the
model chosen and susceptibility to outliers.
Subgroup analysis and investigation of heterogeneity
Subgroup analysis was to be used to explore possible sources of
heterogeneity (e.g. participants, interventions and study quality).
Heterogeneity among participants could be related to age, urinary
pathogen (including urinary bacterial cell counts), chronicity of
symptoms before seeking medical advice, and history of urinary
symptoms (including recurrent UTIs). If data were available we
planned subgroup analysis comparing the use of urinary alkalisers
in sporadic and recurrentUTIs.Heterogeneity in treatments could
be related to prior or concomitant (or both) agent(s) used and
the agent, dose and duration of therapy. These could include an-
tibiotics, analgesics and anti-inflammatory medications. We also
planned subgroup analysis comparing doses and duration of uri-
nary alkaliser therapy. Adverse effects were to be tabulated and
assessed using descriptive techniques because they were likely to
be different for the various agents used. Where possible, the risk
difference with 95% CI was to be calculated for each adverse ef-
fect, either compared with no treatment or another agent.
Sensitivity analysis
We planned sensitivity analyses to explore the influence of the
following factors on effect size.
• Repeating the analysis excluding unpublished studies
• Repeating the analysis taking account of risk of bias, as
specified
• Repeating the analysis excluding any very long or large
studies to establish how much they dominate the results
• Repeating the analysis excluding studies using the following
filters: diagnostic criteria, language of publication, source of
funding (industry versus other), and country.
R E S U L T S
Description of studies
Results of the search
Searches yielded 172 records, of which 29 were duplicates. We
assessed 143 records based on title and abstract and excluded 137
records that did not fulfil our inclusion criteria (Figure 1). We
identified six records for possible inclusion and full-text assess-
ment (Brumfitt 1990; Butler 1983; Carter 1991; Darioli 1983;
Klastersky 1971; Reeves 1984). Reasons for exclusion were inap-
propriate intervention used (Klastersky 1971; Butler 1983;Darioli
1983; Reeves 1984), no urinary alkaliser used (Brumfitt 1990),
and symptoms in the context of urethral instrumentation (Carter
1991). See Characteristics of excluded studies.
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Figure 1. Flow chart
Thus, no studies could be included in this review.
Risk of bias in included studies
Risk of bias assessment could not be conducted.
Effects of interventions
No studies met our inclusion criteria.
D I S C U S S I O N
Summary of main results
Wewere surprised to find no RCTs investigating the use of urinary
alkalisers for uncomplicated UTIs, given the widespread use of
these agents in some parts of the world.Due to the lack of adequate
research into the use of urinary alkalisers for this indication, we
were unable to offer conclusions about their efficacy.
Research supporting the use of urinary alkalisers to date have been
single arm studies (Munday 1990; Spooner 1984). The lack of
a comparison group in these studies precludes any conclusion of
efficacy. The only studies to randomise groups to different inter-
vention arms with urinary alkalisers confounded the comparisons
by using different antibiotics in combination (Butler 1983; Reeves
1984).
The mechanism of action suggested for urinary alkalisers in UTI
is that raising urine pH directly, by local action, reduces symptom
severity on bladder and urethral mucosa. However an observa-
tional study of 128 women with uncomplicated UTIs found no
correlation between reported symptoms of UTI (or infection) and
urine pH (Brumfitt 1990).
Overall completeness and applicability of
evidence
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There is a lack of evidence for the use of urinary alkalisation in the
treatment of lower urinary tract symptoms, particularly in the set-
ting of uncomplicated UTIs. There have been a number of papers
published wherein the researchers investigate the use of urinary
alkalisers for symptomatic relief following or prophylactically for
different urological procedures and investigations, such as flexible
cystoscopy and urodynamics studies (Nguan 2005; Wong 2010).
These papers failed to show any benefit of the use of urinary alka-
lisers. The relevance of these studies to our review question is not
clear however.
There have been no RCTs particularly looking at the use of urinary
alkalisers for uncomplicated UTI in the cohort of patients that we
wished to study.
Quality of the evidence
Research on urinary alkalisation for lower urinary tract symptoms
has not been robust. In the studies we identified, subject num-
bers were small. Groups have been quasi-randomised or not ran-
domised at all and intervention arms are inappropriate to show
effect.
Potential biases in the review process
There were no published RCTs.
Agreements and disagreements with other
studies or reviews
Despite extensive literature searches we were unable to find any
other studies or reviews on this topic.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Currently there is insufficient evidence to support the use of uri-
nary alkalisers for symptoms in acute uncomplicated UTI.
Implications for research
Research is needed to investigate urinary alkalisers for uncompli-
cated UTIs with well-constructed RCTs.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by year of study]
Study Reason for exclusion
Klastersky 1971 This paper compared an antibiotic (erythromycin) in alkaline conditionswith a different antibiotic (nitrofurantoin)
. Although this paper included a urinary alkaliser, the fact that it was coupled with a different antibiotic to the
other study arm means that no conclusions on the efficacy of the alkaliser can be made by comparison of these two
groups. Furthermore most of the patients in this study had advanced pelvic cancers, some had urological issues,
and some had indwelling urinary catheters meaning that they did not meet inclusion criteria for this review
Darioli 1983 This study compared a single dose of urinary alkaliser with a single dose of an antibiotic. A single dose of an
antibiotic is not an accepted treatment for UTI, and therefore is not an appropriate comparison. The aim of this
study was actually to investigate the use of a single dose of antibiotic, and the alkaliser arm was acting as a placebo
arm. Furthermore a single dose of urinary alkaliser is not an appropriate dose to change urinary pH
Butler 1983 This paper compared an antibiotic (nalidixic acid) coupled with a urinary alkaliser (citrate) with a different
antibiotic (cotrimoxazole). As in the Klastersky 1971 paper above, no conclusions on the efficacy of the urinary
alkaliser can be made from comparison of the two arms in this study
Reeves 1984 Similar to Klastersky 1971 and Butler 1983, this paper compared an antibiotic (nalidixic acid) coupled with a
urinary alkaliser (citrate) with a different antibiotic norfloxacin. No conclusions on the efficacy of the urinary
alkaliser can be drawn from this comparison
Brumfitt 1990 This paper reported on the different urinary pHs seen in patients with ’cystitis’. However, there was no intervention,
no urinary alkaliser used
Carter 1991 This study reported on the use of urinary alkalisers for prophylaxis against dysuria following urological intervention.
Because there was instrumentation of the urethra/bladder in this study the patients were not eligible for inclusion
into this review
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. Electronic search strategies
Database Search terms
CENTRAL 1. urinary next tract next infection*:ti,ab,kw
2. bacteriuri*:ti,ab,kw
3. cystitis:ti,ab,kw
4. pyelonephritis:ti,ab,kw
5. (uti or utis):ti,ab,kw
6. {or #1-#5}
7. dysuria:ti,ab,kw
8. stranguria:ti,ab,kw
9. ((pain* or frequen* or urgency) near/25 (micturation or urin*)):ti,ab,kw
10. {or #7-#9}
11. #6 or #10
12. sodium next bicarbonate:ti,ab,kw
13. citrate*:ti,ab,kw
14. “citric acid”:ti,ab,kw
15. alkali*:ti,ab,kw
16. {or #12-#15}
17. #11 and #16
MEDLINE 1. urinary tract infections/
2. bacteriuria/
3. cystitis/
4. Pyelonephritis/
5. urinary tract infection*.tw.
6. (uti or utis).tw.
7. bacteriuri*.tw.
8. cystitis.tw.
9. pyelonephritis.tw.
10. or/1-9
11. Dysuria/
12. stranguria.tw.
13. dysuria.tw.
14. ((pain* or frequen* or urgency) adj25 (micturation or urin*)).tw.
15. or/11-14
16. or/10,15
17. Sodium Bicarbonate/
18. exp Citrates/
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(Continued)
19. sodium bicarbonate.tw,nm.
20. citrate.tw,nm.
21. alkali*.tw.
22. or/17-21
23. and/16,22
EMBASE 1. Urinary Tract Infection/
2. Bacteriuria/
3. Asymptomatic Bacteriuria/
4. Cystitis/
5. exp Pyelonephritis/
6. urinary tract infection*.tw.
7. (uti or utis).tw.
8. bacteriuri*.tw.
9. cystitis.tw.
10. pyelonephritis.tw.
11. or/1-10
12. Dysuria/
13. Urinary Urgency/
14. Urinary Frequency/
15. stranguria.tw.
16. dysuria.tw.
17. ((pain* or frequen* or urgency) adj25 (micturation or urin*)).tw.
18. or/12-17
19. or/11,18
20. Alkalinization/
21. Bicarbonate/
22. Citric Acid/
23. Citrate Sodium/
24. Citrate Potassium Sodium/
25. Citrate Potassium/
26. sodium bicarbonate.tw.
27. citrate*.tw,rn.
28. alkali*.tw.
29. or/20-28
30. and/19,29
Appendix 2. Risk of bias assessment tool
Potential source of bias Assessment criteria
Random sequence generation
Selection bias (biased allocation to interventions) due to inade-
quate generation of a randomised sequence
Low risk of bias: Random number table; computer random num-
ber generator; coin tossing; shuffling cards or envelopes; throwing
dice; drawing of lots; minimization (minimization may be imple-
mented without a random element, and this is considered to be
equivalent to being random)
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(Continued)
High risk of bias: Sequence generated by odd or even date of birth;
date (or day) of admission; sequence generated by hospital or
clinic record number; allocation by judgement of the clinician; by
preference of the participant; based on the results of a laboratory
test or a series of tests; by availability of the intervention
Unclear: Insufficient information about the sequence generation
process to permit judgement
Allocation concealment
Selection bias (biased allocation to interventions) due to inade-
quate concealment of allocations prior to assignment
Low risk of bias: Randomisation method described that would not
allow investigator/participant to know or influence intervention
group before eligible participant entered in the study (e.g. central
allocation, including telephone, web-based, and pharmacy-con-
trolled, randomisation; sequentially numbered drug containers of
identical appearance; sequentially numbered, opaque, sealed en-
velopes)
High risk of bias:Using an open random allocation schedule (e.g. a
list of random numbers); assignment envelopes were used without
appropriate safeguards (e.g. if envelopes were unsealed or non-
opaque or not sequentially numbered); alternation or rotation;
date of birth; case record number; any other explicitly unconcealed
procedure
Unclear: Randomisation stated but no information on method
used is available
Blinding of participants and personnel
Performance bias due to knowledge of the allocated interventions
by participants and personnel during the study
Low risk of bias: No blinding or incomplete blinding, but the re-
view authors judge that the outcome is not likely to be influenced
by lack of blinding; blinding of participants and key study per-
sonnel ensured, and unlikely that the blinding could have been
broken
High risk of bias: No blinding or incomplete blinding, and the
outcome is likely to be influenced by lack of blinding; blinding
of key study participants and personnel attempted, but likely that
the blinding could have been broken, and the outcome is likely
to be influenced by lack of blinding
Unclear: Insufficient information to permit judgement
Blinding of outcome assessment
Detection bias due to knowledge of the allocated interventions by
outcome assessors
Low risk of bias:Noblinding of outcome assessment, but the review
authors judge that the outcome measurement is not likely to be
influenced by lack of blinding; blinding of outcome assessment
ensured, and unlikely that the blinding could have been broken
High risk of bias: No blinding of outcome assessment, and the
outcome measurement is likely to be influenced by lack of blind-
ing; blinding of outcome assessment, but likely that the blinding
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(Continued)
could have been broken, and the outcome measurement is likely
to be influenced by lack of blinding
Unclear: Insufficient information to permit judgement
Incomplete outcome data
Attrition bias due to amount, nature or handling of incomplete
outcome data
Low risk of bias: No missing outcome data; reasons for missing
outcome data unlikely to be related to true outcome (for survival
data, censoring unlikely to be introducing bias); missing outcome
data balanced in numbers across intervention groups, with similar
reasons for missing data across groups; for dichotomous outcome
data, the proportion ofmissing outcomes comparedwith observed
event risk not enough to have a clinically relevant impact on the
intervention effect estimate; for continuous outcome data, plau-
sible effect size (difference in means or standardized difference in
means) among missing outcomes not enough to have a clinically
relevant impact on observed effect size; missing data have been
imputed using appropriate methods
High risk of bias: Reason for missing outcome data likely to be
related to true outcome, with either imbalance in numbers or rea-
sons for missing data across intervention groups; for dichotomous
outcome data, the proportion ofmissing outcomes comparedwith
observed event risk enough to induce clinically relevant bias in
intervention effect estimate; for continuous outcome data, plau-
sible effect size (difference in means or standardized difference in
means) among missing outcomes enough to induce clinically rel-
evant bias in observed effect size; ‘as-treated’ analysis done with
substantial departure of the intervention received from that as-
signed at randomisation; potentially inappropriate application of
simple imputation
Unclear: Insufficient information to permit judgement
Selective reporting
Reporting bias due to selective outcome reporting
Low risk of bias: The study protocol is available and all of the
study’s pre-specified (primary and secondary) outcomes that are of
interest in the review have been reported in the pre-specified way;
the study protocol is not available but it is clear that the published
reports include all expected outcomes, including those that were
pre-specified (convincing text of this nature may be uncommon)
High risk of bias: Not all of the study’s pre-specified primary out-
comes have been reported; one or more primary outcomes is re-
ported using measurements, analysis methods or subsets of the
data (e.g. subscales) that were not pre-specified; one or more re-
ported primary outcomes were not pre-specified (unless clear jus-
tification for their reporting is provided, such as an unexpected
adverse effect); one or more outcomes of interest in the review are
reported incompletely so that they cannot be entered in a meta-
analysis; the study report fails to include results for a key outcome
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that would be expected to have been reported for such a study
Unclear: Insufficient information to permit judgement
Other bias
Bias due to problems not covered elsewhere in the table
Low risk of bias: The study appears to be free of other sources of
bias.
High risk of bias: Had a potential source of bias related to the spe-
cific study design used; stopped early due to some data-dependent
process (including a formal-stopping rule); had extreme baseline
imbalance; has been claimed to have been fraudulent; had some
other problem
Unclear: Insufficient information to assess whether an important
risk of bias exists; insufficient rationale or evidence that an iden-
tified problem will introduce bias
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Antacids [∗urine]; Anti-InfectiveAgents,Urinary [therapeutic use];Hydrogen-IonConcentration [drug effects];UrinaryTract Infections
[∗drug therapy; urine]; Urine [chemistry]
MeSH check words
Adult; Female; Humans
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